ICU Medical (ICUI) to Release Earnings on Tuesday

ICU Medical (NASDAQ:ICUI) will likely be issuing its quarterly earnings data after the market closes on Tuesday, February 25th. Analysts expect the company to announce earnings of $1.48 per share and revenue of $599.10 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

ICU Medical Stock Up 1.2 %

NASDAQ ICUI opened at $160.16 on Tuesday. ICU Medical has a 1 year low of $93.36 and a 1 year high of $196.26. The stock has a market capitalization of $3.92 billion, a PE ratio of -35.05 and a beta of 0.63. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The business’s 50-day moving average is $160.85 and its 200 day moving average is $165.12.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ICUI shares. KeyCorp boosted their target price on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price for the company in a research report on Wednesday, December 11th. Finally, StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $199.67.

Insider Buying and Selling at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $162.91, for a total transaction of $1,954,920.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $17,039,245.63. This trade represents a 10.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Christian B. Voigtlander sold 1,430 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $158.00, for a total value of $225,940.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,737 shares of company stock valued at $2,879,752. 6.70% of the stock is currently owned by company insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.